Exploring the Genetics of Schizophrenia in Manitoba

What this study is about

Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.

Who can join (things the study team will check)

✅ You may be able to join if…

• Individuals aged 18 years and older,
• Reside in Manitoba,
• Involved in the EPPIS, STEP, PACT, ACT/FACTT clinics,
• Clinical diagnosis of schizophrenia using standard DSM-5 criteria,
• Previously consented and enrolled in the MPR.

🚫 You may not be able to join if…

• There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.

Where this trial is running

• University of Manitoba, Winnipeg, Manitoba, Canada

Who to contact

Kaarina Kowalec, PhD · 204-619-5711 · kaarina.kowalec@umanitoba.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07656870.